Ex­clu­sive: Au­toim­mune CAR-T biotech Kyver­na Ther­a­peu­tics is con­sid­er­ing an IPO next month

Kyver­na Ther­a­peu­tics, one of the clin­i­cal-stage biotechs at the fore­front of CAR-T cell ther­a­py’s ex­pan­sion in­to au­toim­mune dis­eases, is con­sid­er­ing an IPO as ear­ly as next month, peo­ple fa­mil­iar with the com­pa­ny’s think­ing told End­points News.

The Cal­i­for­nia biotech could seek a list­ing short­ly be­fore Valen­tine’s Day, ac­cord­ing to the in­di­vid­u­als, who asked not to be iden­ti­fied to dis­cuss con­fi­den­tial mat­ters. The com­pa­ny could re­veal its IPO fil­ing as ear­ly as next week, though it’s al­so pos­si­ble that plans could change.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER